BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 376140)

  • 1. Status report of 376 mycosis fungoides patients at 4 years: Mycosis Fungoides Cooperative Group.
    Lamberg SI; Green SB; Byar DP; Block JB; Clendenning WE; Epstein EH; Fuks ZY; Golitz LE; Lorincz AL; Michel B; Roenigk HH; Van Scott EJ; Vonderheid EC; Thomas RJ
    Cancer Treat Rep; 1979 Apr; 63(4):701-7. PubMed ID: 376140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
    Kim YH; Bishop K; Varghese A; Hoppe RT
    Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
    Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
    Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous T-cell lymphoma.
    Lansigan F; Choi J; Foss FM
    Hematol Oncol Clin North Am; 2008 Oct; 22(5):979-96, x. PubMed ID: 18954747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycosis fungoides and the Sézary syndrome.
    Kim YH; Hoppe RT
    Semin Oncol; 1999 Jun; 26(3):276-89. PubMed ID: 10375085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electron-beam therapy for mycosis fungoides: the Stanford University experience.
    Hoppe RT; Cox RS; Fuks Z; Price NM; Bagshaw MA; Farber EM
    Cancer Treat Rep; 1979 Apr; 63(4):691-700. PubMed ID: 109207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective 5-year review of 131 patients with mycosis fungoides and Sézary syndrome seen at the National Skin Centre, Singapore.
    Tan ES; Tang MB; Tan SH
    Australas J Dermatol; 2006 Nov; 47(4):248-52. PubMed ID: 17034466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycosis fungoides--a review of the management of 28 patients and of the recent literature.
    Lenane P; Powell FC; O'Keane C; Dervan P; O'Sullivan D; Bourke E; O'Loughlin S
    Int J Dermatol; 2007 Jan; 46(1):19-26. PubMed ID: 17214715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A practical approach to accurate classification and staging of mycosis fungoides and Sézary syndrome.
    Thomas BR; Whittaker S
    Skin Therapy Lett; 2012 Dec; 17(10):5-9. PubMed ID: 23223768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome.
    Klemke CD; Mansmann U; Poenitz N; Dippel E; Goerdt S
    Br J Dermatol; 2005 Jul; 153(1):118-24. PubMed ID: 16029336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 10-year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapy.
    Vonderheid EC; Van Scott EJ; Wallner PE; Johnson WC
    Cancer Treat Rep; 1979 Apr; 63(4):681-9. PubMed ID: 109206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis.
    Kim YH; Jensen RA; Watanabe GL; Varghese A; Hoppe RT
    Arch Dermatol; 1996 Nov; 132(11):1309-13. PubMed ID: 8915308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous T cell lymphomas: mycosis fungoides, Sézary syndrome and lymphomatoid papulosis--Part I.
    Safai B
    Clin Bull; 1977; 7(3):91-7. PubMed ID: 308870
    [No Abstract]   [Full Text] [Related]  

  • 14. Memorials and mandates for cutaneous lymphomas.
    Heald PW
    Arch Dermatol; 2003 Jul; 139(7):926-8. PubMed ID: 12873891
    [No Abstract]   [Full Text] [Related]  

  • 15. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome.
    Trautinger F; Knobler R; Willemze R; Peris K; Stadler R; Laroche L; D'Incan M; Ranki A; Pimpinelli N; Ortiz-Romero P; Dummer R; Estrach T; Whittaker S
    Eur J Cancer; 2006 May; 42(8):1014-30. PubMed ID: 16574401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
    Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
    Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.
    Hughes CF; Newland K; McCormack C; Lade S; Prince HM
    Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
    Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
    Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycosis fungoides: cutaneous T-cell lymphoma.
    Zaim MT; Grinkemeyer MD
    Am Fam Physician; 1991 May; 43(5):1703-7. PubMed ID: 2021105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of mycosis fungoides. Part 1. Diagnosis, staging, and prognosis.
    Smith BD; Wilson LD
    Oncology (Williston Park); 2003 Sep; 17(9):1281-8. PubMed ID: 14569854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.